Detalles de la búsqueda
1.
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Ann Oncol
; 34(9): 772-782, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37399894
2.
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Ann Oncol
; 34(7): 605-614, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37164128
3.
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Ann Oncol
; 33(8): 750-768, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35809752
4.
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Ann Oncol
; 32(9): 1157-1166, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34129855
5.
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Ann Oncol
; 32(6): 726-735, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794293
6.
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Ann Oncol
; 30(12): 1992-2003, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31560068
7.
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Ann Oncol
; 29(5): 1235-1248, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29529169
8.
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Ann Oncol
; 28(1): 90-95, 2017 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28039155
9.
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Ann Oncol
; 28(10): 2472-2480, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28961847
10.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Ann Oncol
; 28(7): 1508-1516, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28472366
11.
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Br J Cancer
; 112(10): 1717-24, 2015 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25897673
12.
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
Br J Cancer
; 112(7): 1166-74, 2015 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-25719830
13.
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
Ann Oncol
; 31(3): 442, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32067690
14.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Ann Oncol
; 26(8): 1589-604, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26041764
15.
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer.
Clin Radiol
; 70(4): 359-65, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25555314
16.
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Br J Cancer
; 111(12): 2248-53, 2014 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25314055
17.
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.
Br J Cancer
; 111(5): 828-36, 2014 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-24983367
18.
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Ann Oncol
; 25(3): 657-662, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24458472
19.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Ann Oncol
; 30(12): e3, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27141017
20.
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
Br J Cancer
; 109(2): 325-31, 2013 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23807167